Botanical Drug Sponsors Would Benefit From Simpler Indications – FDAer

Sponsoring botanical drug products with indications for less complex diseases - especially those that are currently without effective treatment - could speed up FDA's review of new botanical drugs, according to Shaw Chen, MD, PhD, Associate Director of CDER's Office of Drug Evaluation I